Kirkland Advises Amicus Therapeutics on $4.8 Billion Sale to BioMarin

Kirkland & Ellis advised Amicus Therapeutics (Nasdaq: FOLD) on a definitive agreement in which BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the boards of directors of both companies, and Amicus' board of directors unanimously recommended that Amicus' stockholders vote to adopt the agreement. The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.

The acquisition will strengthen BioMarin's commercial portfolio, adding two new treatments to the company's existing portfolio of medicines that target lysosomal storage disorders: Galafold (migalastat), the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), a two-component therapy for Pompe disease. Amicus also has U.S. rights to DMX-200, a potential first-in-class investigational small molecule for the treatment of focal segmental glomerulosclerosis (FSGS), a rare and fatal kidney disease in Phase 3 development.

Read the transaction press release

The Kirkland team included corporate lawyers Graham Robinson, Chadé Severin, John Sheridan, Adam Hustad, Lara Pillay, Cem Albayrak, Matthew Kelley, Amy Tong, Cameron Smith, Julianne Turner and Jennifer Leserman; antitrust & competition lawyers Maria Raptis; Samantha Morelli, Adam Gomes-Abreu, Daniel Rosenthal and Joe Krisko; executive compensation lawyers Timothy Nelson, Kelsie Harris and Andrea Rosato; employee benefits lawyers Justin Coddington and Ethan Kirner; healthcare lawyers Dennis Williams, William Shackleton Richmond, Brian King and Olivia Kaufmann; tax lawyers Dean Shulman, Liam Murphy and Olivia Chilcott; technology & IP transactions lawyers Seth Traxler, Shellie Freedman, Amber Harezlak and Jackie Orfield; employment & labor lawyers Mari Stonebraker and Olivia Hunter; debt finance lawyers Rachael Lichman, Daniel Kirksey and John Ryan Isaacson; capital markets lawyers Sophia Hudson and Jennifer Lee; international trade & national security lawyers John Kabealo, Luci Hague and Chad Crowell; and litigation lawyers William Pruitt, David Cummings, Armando Prather, Stefan Atkinson and Alyssa Scruggs.